TGF-β signaling in diseases
TGF-β signaling in diseases is a research topic within Molecular Biology. Science Explorer counts 18k research works in it since 1953. 20.8% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the diverse aspects of the Transforming Growth Factor Beta (TGF-ß) signaling pathway, including its role in Smad-dependent and Smad-independent pathways, tumor suppression, cancer progression, bone morphogenetic protein (BMP) signaling, immune response modulation, cell differentiation, metastasis, regulation of epithelial-mesenchymal transition (EMT), and angiogenesis. It also discusses the development and use of TGF-ß inhibitors for potential therapeutic interventions.
- Smad-dependent pathways
- Tumor Suppression
- Cancer Progression
- BMP signaling
- Immune Response
- Cell Differentiation
- Metastasis
- Regulation of EMT
- Angiogenesis
- TGF-ß Inhibitors
- Research works
- 18k fractional, since 1953
- In the world top 10%
- 3.7k per year above
- Top-10% rate
- 20.8% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -20% the tick is no change
Which countries lead TGF-β signaling in diseases research?
By volume, China and the United States publish the most (624 and 256 works in 2022–2025).
By volume, 2022–2025
- 1 China 624 works
- 2 United States 256 works
- 3 Japan 76 works
- 4 Germany 53 works
- 5 South Korea 48 works
- 6 India 47 works
- 7 United Kingdom 39 works
- 8 France 31 works
- 9 Iran 26 works
- 10 Canada 25 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead TGF-β signaling in diseases research?
By volume in 2022–2025, Chongqing Medical University publishes the most TGF-β signaling in diseases research, followed by Sichuan University and Sun Yat-sen University.
By volume, 2022–2025
- 1 Chongqing Medical UniversityChina 8 works
- 2 Sichuan UniversityChina 8 works
- 3 Sun Yat-sen UniversityChina 8 works
- 4 Shanghai Jiao Tong UniversityChina 6 works
- 5 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 6 works
- 6 Peking UniversityChina 6 works
- 7 Central South UniversityChina 6 works
- 8 Wuhan UniversityChina 6 works
- 9 Zhejiang UniversityChina 6 works
- 10 Fujian Medical UniversityChina 6 works
Who are the leading researchers in TGF-β signaling in diseases?
The most-cited researchers publishing on TGF-β signaling in diseases include Bert Vogelstein, Peter R. Galle and A.G. Evans.
- 1 Bert Vogelstein United States 7.1k citations
- 2 Peter R. Galle Germany 3.3k citations
- 3 A.G. Evans United States 3.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is TGF-β signaling in diseases research done?
The largest centres of TGF-β signaling in diseases research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Hangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Jinan.
Largest cities, 2022–2025
Where it is the local speciality
- JinanCN · 20.8 works3.5×
Location quotient: how much more of its research is in TGF-β signaling in diseases than the world average.
Is TGF-β signaling in diseases research growing?
Output in 2018–2022 was 20% lower than in 2013–2017, peaking in 2013.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.